Video

Dr. Harrison on 5-Year Follow-Up Data on Ruxolitinib in Patients With Myelofibrosis

Claire Harrison, MD, deputy clinical director of Cancer and Hematology, Guy's and St. Thomas' NHS, discusses 5-year follow-up data examining ruxolitinib in patients with myelofibrosis.

Claire Harrison, MD, deputy clinical director of Cancer and Hematology, Guy's and St. Thomas' NHS, discusses 5-year follow-up data examining ruxolitinib in patients with myelofibrosis.

The phase III COMFORT-II study is known as one of the clinical trials that led to ruxolitinib’s FDA approval, Harrison explains. Myelofibrosis is a malignancy associated with splenomegaly, significant constitutional symptoms, and a reduction in life expectancy. Initial data released from the study demonstrated that, upon treatment with ruxolitinib, patients had a significant improvement in quality of life and a reduction in spleen size. Follow-up data showed that the agent also prolonged survival in patients.

The 5-year follow-up results of the study represents a high volume of patient data for myelofibrosis, Harrison says. The long-term data showed a reduction in spleen volume in 35% of patients. Moreover, reductions in JAK2 V617F allele burden occurred in 80% to 100% of patients, she adds.

<<<

View more from the 2015 ASH Annual Meeting

Related Videos
Michael R. Grunwald, MD, FACP
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Daniel DeAngelo, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Daniel DeAngelo, MD, PhD